A Phase 3 Study of Rezpegaldesleukin (NKTR-358) for Patients ≥ 12 Years of Age With Moderate-to-Severe Atopic Dermatitis (ZENITH AD-2)
2026年9月4日 更新者:Nektar Therapeutics
A Phase 3, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Rezpegaldesleukin (NKTR-358) Monotherapy in the Treatment of Patients ≥ 12 Years of Age With Moderate-to- Severe Atopic Dermatitis
This is an interventional, randomized, parallel group, treatment, Phase 3, double blind study to assess the effect of Rezpegaldesleukin in participants 12 years of age or older with moderate to severe atopic dermatitis, as compared to placebo.
The estimated participant overall duration is approximately 15 months.
調査の概要
研究の種類
介入
入学 (推定)
510
段階
- フェーズ 3
連絡先と場所
このセクションには、調査を実施する担当者の連絡先の詳細と、この調査が実施されている場所に関する情報が記載されています。
研究連絡先
- 名前:Nektar Recruitment
- 電話番号:855-482-8676
- メール:StudyInquiry@nektar.com
研究場所
-
-
Alabama
-
Birmingham、Alabama、アメリカ、35203
- 募集
- Nektar Investigative Site
-
-
California
-
Oxnard、California、アメリカ、93030
- 募集
- Nektar Investigative Site
-
Palmdale、California、アメリカ、93551
- 募集
- Nektar Investigative Site
-
Sacramento、California、アメリカ、95815
- 募集
- Nektar Investigative Site
-
-
Florida
-
Tamarac、Florida、アメリカ、33321
- 募集
- Nektar Investigative Site
-
-
Georgia
-
Savannah、Georgia、アメリカ、31406
- 募集
- Nektar Investigative Site
-
-
Louisiana
-
Metairie、Louisiana、アメリカ、70006
- 募集
- Nektar Investigative Site
-
-
Missouri
-
Kirksville、Missouri、アメリカ、63501
- 募集
- Nektar Investigative Site
-
Lee's Summit、Missouri、アメリカ、64064
- 募集
- Nektar Investigative Site
-
-
Nevada
-
Las Vegas、Nevada、アメリカ、89144
- 募集
- Nektar Investigative Site
-
-
New Jersey
-
Robbinsville、New Jersey、アメリカ、08691
- 募集
- Nektar Investigative Site
-
-
New York
-
The Bronx、New York、アメリカ、10455
- 募集
- Nektar Investigative Site
-
-
Ohio
-
Columbus、Ohio、アメリカ、43213
- 募集
- Nektar Investigative Site
-
-
参加基準
研究者は、適格基準と呼ばれる特定の説明に適合する人を探します。これらの基準のいくつかの例は、人の一般的な健康状態または以前の治療です。
適格基準
就学可能な年齢
- 子
- 大人
- 高齢者
健康ボランティアの受け入れ
いいえ
説明
Inclusion Criteria:
- Male or female patients, ≥ 12 years of age on the day of signing the informed consent form and weighing ≥ 40 kg prior to randomization at Baseline
Chronic atopic dermatitis (AD) defined as onset of AD signs and symptoms
≥ 12 months prior to Screening as determined by the Investigator through patient interview and/or review of medical history at the Screening Visit
- Patients must meet the following AD severity criteria:
- IGA score ≥ 3 (scale of 0 to 4) at Screening and Baseline
- ≥ 10.0% of BSA involvement at Screening and Baseline
- EASI ≥ 16.0 at Screening and Baseline
- Are candidates for systemic therapy and have history, documented by a physician and/or the Investigator, of inadequate response to existing topical medications within 6 months preceding Screening, or history of intolerance to a topical therapy
- Provide written, informed consent to participate in the study and follow the study procedures, including compliance with the use of highly effective contraceptives
Exclusion Criteria:
- Are currently experiencing or have a history of concomitant skin conditions other than AD, including skin infection in the area affected by the patient's AD that requires treatment with systemic antimicrobial therapy
- Are currently experiencing or have a history of unstable course of AD
- History of chronic idiopathic urticaria at any time or urticaria from other causes within 4 weeks prior to randomization at the Baseline Visit.
- Have a history of TCS use suggestive of a high risk for topical corticosteroid (TCS) withdrawal
- Have received any of the following treatments at any time before Screening: aldesleukin; investigational IL-2 analog; systemic biologic; oral JAKi; or any prior investigational agent for AD
- Have a current or recent acute, active infection
研究計画
このセクションでは、研究がどのように設計され、研究が何を測定しているかなど、研究計画の詳細を提供します。
研究はどのように設計されていますか?
デザインの詳細
- 主な目的:処理
- 割り当て:ランダム化
- 介入モデル:並列代入
- マスキング:4倍
武器と介入
参加者グループ / アーム |
介入・治療 |
|---|---|
|
実験的:Blinded Induction Period: Rezpegaldesleukin every 2 weeks
Rezpegaldesleukin every 2 weeks during the induction period
|
剤形:注射液投与経路:皮下投与
他の名前:
|
|
プラセボコンパレーター:Blinded Induction Period: Placebo
Placebo every 2 weeks during the induction period
|
剤形:注射液投与経路:皮下投与
|
|
実験的:Blinded Maintenance Period: Rezpegaldesleukin every 4 weeks
Rezpegaldesleukin every 4 weeks during the maintenance period
|
剤形:注射液投与経路:皮下投与
他の名前:
|
|
実験的:Blinded Maintenance Period: Rezpegaldesleukin every 12 weeks
Rezpegaldesleukin every 12 weeks during the maintenance period
|
剤形:注射液投与経路:皮下投与
他の名前:
|
|
プラセボコンパレーター:Blinded Maintenance Period: Placebo
Placebo every 4 weeks during the maintenance period
|
剤形:注射液投与経路:皮下投与
|
|
実験的:Open-Label Escape
Rezpegaldesleukin at a frequency determined by the investigator during the open-label escape
|
剤形:注射液投与経路:皮下投与
他の名前:
|
この研究は何を測定していますか?
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
US only: Number of participants with an Investigator's Global Assessment (IGA) score of 0 or 1 and reduction ≥ 2 points from baseline at Week 24
時間枠:Week 0 and Week 24
|
The IGA scale ranges from 0 to 4, with higher score indicating more severe disease.
|
Week 0 and Week 24
|
|
Non-US regions only: Number of participants with an Investigator's Global Assessment (IGA) score of 0 or 1 at Week 24
時間枠:Week 0 and Week 24
|
The IGA scale ranges from 0 to 4, with higher score indicating more severe disease.
|
Week 0 and Week 24
|
|
Non-US regions only: Number of participants with a ≥ 75% reduction in Eczema Area and Severity Index (EASI) score from baseline at Week 24 (EASI-75)
時間枠:Week 0 and Week 24
|
The EASI scores range from 0 to 72, with higher scores indicating more severe atopic dermatitis.
|
Week 0 and Week 24
|
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
US only: Number of participants with a ≥ 75% reduction in EASI score from baseline at Week 24 (EASI-75)
時間枠:Week 0 and Week 24
|
The EASI scores range from 0 to 72, with higher scores indicating more severe atopic dermatitis.
|
Week 0 and Week 24
|
|
Number of participants with a ≥ 90% reduction in EASI score from baseline at Week 24 (EASI-90)
時間枠:Week 0 and Week 24
|
The EASI scores range from 0 to 72, with higher scores indicating more severe atopic dermatitis.
|
Week 0 and Week 24
|
|
Number of participants at week 6 achieving a 4-point or greater improvement in Itch numerical rating scale (NRS) in the subset of participants with a 4-point or greater Itch NRS at baseline
時間枠:Week 0 and Week 6
|
The itch NRS goes from 0 to 10, with higher score indicating more severe itch.
|
Week 0 and Week 6
|
|
Number of participants at week 24 achieving a 4-point or greater improvement in Itch numerical rating scale (NRS) in the subset of participants with a 4-point or greater Itch NRS at baseline
時間枠:Week 0 and Week 24
|
The itch NRS goes from 0 to 10, with higher score indicating more severe itch.
|
Week 0 and Week 24
|
|
Number of participants at week 6 achieving a 4-point or greater improvement in Skin Pain numerical rating scale (NRS) in the subset of participants with a 4-point or greater Skin Pain NRS at baseline
時間枠:Week 0 and Week 6
|
The Skin Pain NRS goes from 0 to 10, with higher score indicating more severe pain.
|
Week 0 and Week 6
|
|
Number of participants at week 24 achieving a 4-point or greater improvement in Skin Pain numerical rating scale (NRS) in the subset of participants with a 4-point or greater Skin Pain NRS at baseline
時間枠:Week 0 and Week 24
|
The Skin Pain NRS goes from 0 to 10, with higher score indicating more severe pain.
|
Week 0 and Week 24
|
|
Number of participants at week 6 achieving a 1.25-point or greater improvement in Atopic Dermatitis Sleep Scale Question 1 (ADSS Q1) in the subset of participants with a 1.25-point or greater ADSS Q1 at baseline
時間枠:Week 0 and Week 6
|
The ADSS Q1 goes from 0 to 4, with higher score indicating more difficulty sleeping.
|
Week 0 and Week 6
|
|
Number of participants at week 24 achieving a 1.25-point or greater improvement in ADSS Q1 in the subset of participants with a 1.25-point or greater ADSS Q1 at baseline
時間枠:Week 0 and Week 24
|
The ADSS Q1 goes from 0 to 4, with higher score indicating more difficulty sleeping.
|
Week 0 and Week 24
|
|
Change in Asthma Control Questionnaire-5 (ACQ-5) score from baseline at Week 24 in the subpopulation of patients with a 0.5-point or greater ACQ-5 at baseline
時間枠:Week 0 and Week 24
|
The ACQ-5 goes from 0 to 6, with higher score indicating worse asthma control.
|
Week 0 and Week 24
|
|
Number of participants at week 24 achieving a 0.5-point or greater improvement in ACQ-5 in the subset of participants with a 0.5-point or greater ACQ-5 at baseline
時間枠:Week 0 and Week 24
|
The ACQ-5 goes from 0 to 6, with higher score indicating worse asthma control.
|
Week 0 and Week 24
|
|
Change in Sino-Nasal Outcome Test (SNOT-22) score from baseline at Week 24 in the subpopulation of patients with an 8.9-point or greater SNOT-22 at baseline
時間枠:Week 0 and Week 24
|
The SNOT-22 scores range from 0 to 110, with a higher score indicating more severe symptoms
|
Week 0 and Week 24
|
|
Number of participants at Week 24 achieving a 8.9-point or greater reduction from baseline in SNOT-22 in the subpopulation of patients with an 8.9-point or greater SNOT-22 at baseline
時間枠:Week 0 and Week 24
|
The SNOT-22 scores range from 0 to 110, with a higher score indicating more severe symptoms
|
Week 0 and Week 24
|
|
Number of participants at week 24 achieving an Adapted Investigator's Global Assessment (aIGA) response of 0 or 1
時間枠:Week 0 and Week 24
|
The aIGA scale ranges from 0 to 1, with a lower score indicating improvement in atopic dermatitis.
|
Week 0 and Week 24
|
|
Number of participants with treatment emergent adverse events (TEAEs)
時間枠:Through participant study completion, approximately Week 56
|
Through participant study completion, approximately Week 56
|
|
|
Number of participants with treatment emergent serious adverse events
時間枠:Through participant study completion, approximately Week 56
|
Through participant study completion, approximately Week 56
|
|
|
Number of participants with treatment related serious adverse events
時間枠:Through participant study completion, approximately Week 56
|
Through participant study completion, approximately Week 56
|
|
|
Number of participants with treatment emergent adverse events of special interest
時間枠:Through participant study completion, approximately Week 56
|
Through participant study completion, approximately Week 56
|
|
|
Number of participants with treatment related adverse events of special interest
時間枠:Through participant study completion, approximately Week 56
|
Through participant study completion, approximately Week 56
|
|
|
Number of participants with TEAEs leading to treatment discontinuation
時間枠:Through participant study completion, approximately Week 56
|
Through participant study completion, approximately Week 56
|
|
|
Number of participants with TEAEs leading to dose hold
時間枠:Through participant study completion, approximately Week 56
|
Through participant study completion, approximately Week 56
|
|
|
Number of participants with TEAEs leading to dose modifications
時間枠:Through participant study completion, approximately Week 56
|
Through participant study completion, approximately Week 56
|
協力者と研究者
ここでは、この調査に関係する人々や組織を見つけることができます。
スポンサー
捜査官
- スタディディレクター:Study Director、Nektar Therapeutics
研究記録日
これらの日付は、ClinicalTrials.gov への研究記録と要約結果の提出の進捗状況を追跡します。研究記録と報告された結果は、国立医学図書館 (NLM) によって審査され、公開 Web サイトに掲載される前に、特定の品質管理基準を満たしていることが確認されます。
主要日程の研究
研究開始 (実際)
2026年8月7日
一次修了 (推定)
2028年6月1日
研究の完了 (推定)
2029年1月1日
試験登録日
最初に提出
2026年7月14日
QC基準を満たした最初の提出物
2026年7月14日
最初の投稿 (実際)
2026年7月17日
学習記録の更新
投稿された最後の更新 (実際)
2026年9月8日
QC基準を満たした最後の更新が送信されました
2026年9月4日
最終確認日
2026年9月1日
詳しくは
本研究に関する用語
その他の研究ID番号
- 25-358-10
- 2025 (米国 NIH グラント/契約:Faculty of Social Sciences Scientific Grant at the University of Gdańsk)
- 2025-525129-11-00 (Ctis)
個々の参加者データ (IPD) の計画
個々の参加者データ (IPD) を共有する予定はありますか?
いいえ
医薬品およびデバイス情報、研究文書
米国FDA規制医薬品の研究
はい
米国FDA規制機器製品の研究
いいえ
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。